Farletuzumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Farletuzumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized
Target FR-alpha
Clinical data
Legal status
?
Identifiers
CAS number 896723-44-7 N
ATC code None
UNII 2O09BG0OWA YesY
KEGG D09343 YesY
Chemical data
Formula C6466H9928N1716O2020S42 
Mol. mass 145.4 kDa
 N (what is this?)  (verify)

Farletuzumab (MORAb-003) is a monoclonal antibody[1] which is being investigated for the treatment of ovarian cancer.[2][3]

This drug was developed by Morphotek, Inc.

It is targeted at FR-alpha which is overexpressed in some cancers such as ovarian cancer.

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Farletuzumab, American Medical Association.
  2. ^ ClinicalTrials.gov: Phase II Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer
  3. ^ ClinicalTrials.gov: Phase III Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse